CUMBERLAND, R.I., Sept. 19, 2013 /PRNewswire/ -- Neurotech Pharmaceuticals, a biotechnology company developing sight-saving therapies for chronic retinal disease, announced today that renowned ophthalmology experts Eugene de Juan, Jr., M.D., and Lester Kaplan, Ph.D., have joined the company's board of directors. In addition, former Allergan Vice President and Therapeutic Area Head for ophthalmology, Rhett Schiffman, M.D., M.S., M.H.SA. has joined the company as its Chief Medical Officer.
Along with the Neurotech team, Drs. de Juan and Kaplan will help advance the company's technology platform through the clinical development stage toward market availability. As CMO, Dr. Schiffman will lead the overall clinical development strategy as well as the design and execution of the various clinical programs at Neurotech.
"In our mission to develop therapies for retinal disease, we are incredibly fortunate to count such respected leaders as our own," said Neurotech President and CEO Ted Danse. "Because of their extensive and exhaustive experience in the field of ophthalmology, all three play an integral part in our effort to establish Neurotech as the leader in the fight against blindness."
Jim Mazzo, Neurotech Board of Directors Executive Chairman, remarked, "As we build Neurotech, we searched for the selected few Board members who could make the greatest contribution to the development of our company. That Drs. de Juan and Kaplan have chosen to join us is an immense validation of our cause and our efforts."
Eugene de Juan is a retinal surgeon, inventor
|SOURCE Neurotech USA|
Copyright©2012 PR Newswire.
All rights reserved